Antiviral therapy after non‐surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus

Hung, Chao‐Hung; Lee, Chuan–Mo; Wang, Jing‐Houng; Tung, Hung‐Da; Chen, Chien‐Hung; Lu, Sheng–Nan

doi:10.1111/j.1440-1746.2005.03925.x

Cited by 43 publications

(56 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Several studies have reported the survival benefits of IFN therapy following HCC treatment. 12,[31][32][33] Five-year survival rates of IFN groups were 68-91%. 31,33 In this study, the 5-year survival rate of C-HCC patients treated with IFN-based therapy Figure 1 Overall survival in hepatitis B-related hepatocellular carcinoma patients according to the cohort.…”

Section: Discussionmentioning

confidence: 99%

Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

Minami

Tateishi

Shiina

et al. 2015

Hepatology Research

View full text Add to dashboard Cite

Aim: Treatment strategies for hepatocellular carcinoma (HCC) have been advanced. The aim of this study was to compare the change of the prognosis between hepatitis B-related HCC (B-HCC) and hepatitis C-related HCC (C-HCC) in the last two decades. Results: Two (11%), 24 (49%) and 80 (82%) B-HCC patients received nucleoside/nucleotide analogs during the follow-up period in cohorts 1-3, respectively. Among them 1, 18 and 62 patients achieved viral remission, respectively. Thirty-four (18%), 35 (8%) and 84 (14%) C-HCC patients received interferon therapy, respectively. The 5-year B-HCC (P < 0.001) survival rates were 52.6%, 61.1% and 81.6% for cohorts 1-3, respectively. However, the survival rates were 55.6%, 58.8% and 61.1% for C-HCC (P = 0.12), respectively. The B-HCC prognosis improved dramatically (P < 0.001) over time, whereas the prognosis of C-HCC improved moderately (P = 0.01). Methods: Conclusion:The prognosis of B-HCC has improved dramatically over time, whereas that of C-HCC has improved moderately.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

Minami

Tateishi

Shiina

et al. 2015

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…In that trial, although the difference in the tumor-free survival rate between the IFN group and the control group was small during the early postoperative stage, the incidence of HCC recurrence was low during the late postoperative stage (more than 3 years after surgery) in the IFN group alone. Other studies have also shown that recurrence during the late postoperative stage is suppressed by IFN therapy [26,28,29] . The suppressive effects of IFN therapy on HCC recurrence appeared to be stronger in patients who showed a sustained viral response (SVR).…”

Section: Hcv-related Hccmentioning

confidence: 93%

“…In addition, several studies, including randomized controlled trials regarding the effects of IFN therapy on the outcome of HCC treatment have been conducted [24][25][26][27][28][29][30][31] . We performed a randomized controlled trial on the effects of longterm IFN therapy on the outcome of liver resection for HCV-related HCC, which demonstrated that postoperative IFN therapy decreased HCC recurrence after surgery [25] .…”

Section: Hcv-related Hccmentioning

confidence: 99%

Adjuvant Therapy after Curative Resection for Hepatocellular Carcinoma Associated with Hepatitis Virus

Kubo

Takemura²,

Sakata³

et al. 2013

Liver Cancer

View full text Add to dashboard Cite

The outcome after curative resection for hepatocellular carcinoma (HCC) is still unsatisfactory because of the high rate of recurrence of HCC, including intrahepatic metastasis originating from the primary carcinoma and multicentric carcinogenesis after surgery. The rate of recurrence, particularly of multicentric carcinogenesis after surgery, is affected by persistent active hepatitis and hepatic fibrosis caused by chronic hepatitis B or C. In patients with hepatitis B virus (HBV)-related HCC, a high viral load is a strong risk factor for HCC recurrence. Nucleos(t)ide analogues improve the outcome after curative resection for HBV-related HCC. Interferon therapy improves the outcome after curative resection for hepatitis C virus (HCV)-related HCC by decreasing recurrence and preserving or improving liver function when treatment is successful. Low-dose intermittent interferon therapy has also been reported to be effective in suppressing HCC recurrence. New antiviral agents including protease or polymerase inhibitors are expected to be effective because these agents can eradicate HCV in most patients who receive such treatment.

show abstract

“…Other RCTs, also performed in Japan and Taiwan, failed to find a significant delay in the first recurrence with IFN therapy, but the second or third recurrence was significantly reduced especially in sustained responders and the overall survival was improved [401,402]. Another RCT in Italy did not detect effects of IFN therapy on early recurrence but late recurrence, with more than 2 years of interval, seemed to be reduced among IFN responders [403].…”

Section: Tertiary Prevention Of Hcv-related Hccmentioning

confidence: 96%

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

Introduction The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations. Methods The working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements. 123Hepatol Int (2010) 4: 439-474 DOI 10.1007/s12072-010-9165-7 Results Participants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference.

show abstract

Antiviral therapy after non‐surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus

Abstract: These results indicate that successful antiviral therapy after non-surgical tumor ablation for HCV-related HCC may lower tumor recurrence rate and prolong survival.

Cited by 43 publications

References 33 publications

Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

Adjuvant Therapy after Curative Resection for Hepatocellular Carcinoma Associated with Hepatitis Virus

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

Contact Info

Product

Resources

About